• |
  • CONTACT US
Search
  • Ticker:- BBH;false;MVBBH;
  • Ticker Group:- ETFEQ_IND;false;;

  • Making News

    Zacks Equity Research: Semiconductor ETFs for 2013?


    2/07/13: Zacks Equity Research reports that the semiconductor industry is "set to rebound in 2013 with the recovery projected to pick up speed in the latter part of the year" and advises investors to consider SMH as a vehicle for accessing the space.
    View article >> 


    WSJ: What ETF Managers Do


    1/04/13: Reporter A. Weinberg interviews Market Vectors’ Hao-Hung (Peter) Liao, "who leads a handful of portfolio managers at Van Eck Global who oversee some $24 billion in investor assets around the world." The primary mission of Liao and his ETF team is to keep each Fund’s “holdings and the value of those holdings, precisely in line with the indexes they track."
    View article >> 


    Barron's: Looking Beyond the Patent Cliff


    12/08/12: Barron’s Jack Hough writes, "Not every financial cliff is a dire threat." He’s talking about the drug patent cliff for big pharma companies and calls it just a "menacing pot hole." Hough reports, "as drug makers produce more innovative medicines in coming years, investor confidence is likely to surge," and he recommends ETFs, including PPH, as vehicles for investors to "get broad, low-cost Big Pharma exposure."
    View article >> 


    WSJ: 2012 Biotech Medal Winners…So Far


    8/01/12: “Bio-tech is often an area of contrarian strength in an economically weak environment,” posits the WSJ’s Gil Morales. He discusses how the bio-tech sector has managed to buck market weakness in the first half of 2012. He highlights the strength of BBH, which “tracks a group of companies involved in various segments of the biotechnology industry”, and which has shown “a steady, sustained uptrend which began in 2011.”
    View article >> 

  • How to Purchase

    Learn more

Biotech ETF BBH

  • Full Name: Market Vectors®
    Biotech ETF (BBH)

    Management Style: Replication

    Underlying Index: Market Vectors® US Listed Biotech 25 Index (MVBBHTR)

    Index Description: MVBBHTR is a rules-based index intended to track the overall performance of 25 of the largest U.S. listed, publicly traded biotech companies.

  •    

    • Fund Ticker

      BBH

    • Exchange

      NYSE Arca

    • Index Total Return Ticker

      MVBBHTR

    • Index Provider

      Market Vectors Index Solutions

    • Total Net Assets

      $328.1M

    • Shares Outstanding

      4,496,503

    • Number of Holdings

      26

    • Commencement Date

      12/20/2011

  •   as of 05/17/13

  • Portfolio Composition (%) as of 05/17/13

    • % of Net Assets

    • Stocks

      100.02

    • Bonds

      0.00

    • Other

      0.00

    • Cash

      -0.02

    • Total

      100.00

  • Download All Holdings All Holdings (%) as of 05/17/13

    Total Holdings: 26
    Holding Name
    Ticker
    		 Shares Market Value
    (US$)     		% of Net
    Assets
    Gilead Sciences Inc
    GILD US
    		 838,276 47,194,939 14.38
    Amgen Inc
    AMGN US
    		 416,268 44,155,157 13.46
    Biogen Idec Inc
    BIIB US
    		 131,428 29,814,442 9.09
    Celgene Corp
    CELG US
    		 232,900 29,091,539 8.87
    Vertex Pharmaceuticals Inc
    VRTX US
    		 252,828 20,097,298 6.13
    Regeneron Pharmaceuticals Inc
    REGN US
    		 71,707 19,143,618 5.83
    Alexion Pharmaceuticals Inc
    ALXN US
    		 149,322 15,365,234 4.68
    Life Technologies Corp
    LIFE US
    		 208,762 15,352,357 4.68
    Illumina Inc
    ILMN US
    		 211,892 15,256,224 4.65
    BioMarin Pharmaceutical Inc
    BMRN US
    		 204,363 13,081,276 3.99
    Onyx Pharmaceuticals Inc
    ONXX US
    		 124,259 11,885,373 3.62
    Pharmacyclics Inc
    PCYC US
    		 97,137 8,245,960 2.51
    QIAGEN NV
    QGEN US
    		 399,845 7,457,109 2.27
    Seattle Genetics Inc
    SGEN US
    		 172,146 6,317,758 1.93
    Medivation Inc
    MDVN US
    		 125,133 5,947,571 1.81
    Cubist Pharmaceuticals Inc
    CBST US
    		 113,154 5,602,255 1.71
    United Therapeutics Corp
    UTHR US
    		 76,100 5,263,837 1.60
    Ariad Pharmaceuticals Inc
    ARIA US
    		 310,793 5,180,919 1.58
    Incyte Corp Ltd
    INCY US
    		 205,389 4,732,163 1.44
    Myriad Genetics Inc
    MYGN US
    		 139,050 4,578,917 1.40
    Cepheid Inc
    CPHD US
    		 114,159 4,368,865 1.33
    Charles River Laboratories Internationa
    CRL US
    		 82,305 3,704,548 1.13
    Arena Pharmaceuticals Inc
    ARNA US
    		 375,313 2,994,998 0.91
    Acorda Therapeutics Inc
    ACOR US
    		 69,513 2,289,758 0.70
    Dendreon Corp
    DNDN US
    		 263,991 1,058,604 0.32
    Other/Cash
    		-64,448 -0.02
    Total (%) 100.00
    These are not recommendations to buy or to sell any security. Securities and holdings may vary.
  • Contact Us

    Van Eck Securities
    Corporation, Distributor
    335 Madison Avenue, 19th Fl.
    New York, NY 10017
    888.MKT.VCTR
    888.658.8287
    marketvectors@vaneck.com

  • Important Disclosure

    130-Day SEC Yield is calculated daily, and is a standard yield calculation developed by the Securities and Exchange Commission that allows for fairer comparisons primarily among bond funds. It is based on the most recent 30-day period. This yield figure reflects the interest earned during the period after deducting the fund's expenses for the period. It does not reflect the yield an investor would have received if they had held the fund over the last twelve months assuming the most recent NAV. The 12-Month yield is calculated by summing any income distributions over the past twelve months and dividing by the sum of the most recent NAV and any capital gain distributions made over the past twelve months.

    2Expenses for BBH are capped contractually at 0.35% until at least 2/01/14. Cap excludes certain expenses, such as interest.

    3Morningstar Ratings: ©2013 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. 

    4IIV is an abbreviation for An ETF's intraday indicative value; it is an estimated fair value of its holdings based on the most recent prices of its underlying securities and other assets. Intraday values are typically updated every 15 seconds and should closely approximate the net asset value (NAV) of an ETF throughout the trading day. ETF intraday values are calculated by an exchange (e.g., the NYSE Arca) and are distributed through quote services.

    For each fund with at least a three-year history, Morningstar calculates a Morningstar Rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a fund’s monthly performance (including the effects of sales charges, loads, and redemption fees), placing more emphasis on downward variations and rewarding consistent performance. The top 10% of funds in each category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars and the bottom 10% receive 1 star. (Each share class is counted as a fraction of one fund within this scale and rated separately, which may cause slight variations in the distribution percentages.) The Overall Morningstar Rating for a fund is derived from a weighted average of the performance figures associated with its three-, five- and ten-year (if applicable) Morningstar Rating metrics.

    Investments concentrated in the biotech sector may be subject to more volatility than investments in a diverse group of sectors. They are subject to the risks associated with the sector including, among others, costs associated with research and development, intellectual property rights and regulatory approval by the U.S. Food and Drug Administration. Additionally, the Fund is subject to changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international investing. Investing in securities of small and medium-sized companies may involve greater risk than is customarily associated with investing in large companies. The Fund is considered non-diversified and may be subject to greater risks than a diversified fund. Investors should be willing to accept a high degree of volatility and the potential of significant loss. See the Fund’s prospectus for more complete information regarding investment risks.

    Price/Book Ratio is the price of a security divided by the book value per share of the security. Price/Earnings Ratio is the price of a security divided by the earnings per share of the security.

    Market Vectors US Listed Biotech 25 Index (the “Index”) is the exclusive property of Market Vectors Index Solutions GmbH (a wholly owned subsidiary of the Adviser), which has contracted with Structured Solutions AG to maintain and calculate the Index. Structured Solutions AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards Market Vectors Index Solutions GmbH, Structured Solutions AG has no obligation to point out errors in the Index to third parties. Market Vectors Biotech ETF (the “Fund”) is not sponsored, endorsed, sold or promoted by Market Vectors Index Solutions GmbH and Market Vectors Index Solutions GmbH makes no representation regarding the advisability of investing in the Fund. Index returns are not Fund returns and do not reflect any management fees or brokerage expenses. Investors can not invest directly in the Index. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. Index returns assume that dividends have been reinvested.

    The S&P® 500 Index consists of 500 widely held common stocks covering industrial, utility, financial and transportation sector; as an Index, it is unmanaged and is not a security in which investments can be made.

    The “Net Asset Value” (NAV) of a Market Vectors Exchange Traded Fund (ETF) is determined at the close of each business day, and represents the dollar value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF’s intraday trading value. Market Vectors ETF investors should not expect to buy or sell shares at NAV.

    Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called "creation units" and otherwise can be bought and sold only through exchange trading. Creation units are issued and redeemed principally in kind. Shares may trade at a premium or discount to their NAV in the secondary market. You will incur brokerage expenses when trading Fund shares in the secondary market. Past performance is no guarantee of future results. Returns for actual Fund investments may differ from what is shown because of differences in timing, the amount invested, and fees and expenses.

    Investing involves substantial risk and high volatility, including possible loss of principal. Bonds and bond funds will decrease in value as interest rates rise. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus, which contains this and other information, call 888.MKT.VCTR or visit vaneck.com/etf. Please read the prospectus and summary prospectus carefully before investing. 

    Not FDIC Insured — No Bank Guarantee — May Lose Value  

     

 © 2013 Van Eck Securities Corporation. All rights reserved.